ARTICLE AD BOX
Hong Kong Skyline
Nikada | E+ | Getty Images
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience institution with nary revenue, is the latest speculative overseas banal to pull an antithetic surge successful trading demand.
Shares of Regencell, which says it develops accepted Chinese herb treatments to dainty puerility attraction shortage hyperactivity upset and autism, much than tripled connected Monday — soaring much than 280% by the close. A 38-for-1 split declared connected June 2 took effect connected Monday.
The company's twelvemonth to day show is disconnected the charts too, having risen 46,000% successful 2025. By Monday's close, Regencell, founded successful 2014 and traded connected Nasdaq nether the ticker 'RGC' since 2021, had a full marketplace capitalization of $29.7 billion, according to S&P Capital IQ.
Regencell CEO Yat-Gai Au controls 86.24% of the full fig of shares outstanding, according to FactSet data.
Regencell Bioscience Holdings successful 2025.
Regencell is the latest illustration of a speculative planetary banal attracting attraction during summertime trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, concisely giving it a marketplace worth greater than Coca-Cola and Bank of America.
Regencell's marketplace worth is present astir adjacent with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp.
Earlier this month, Regencell explained the banal divided arsenic designed solely "to heighten liquidity successful the marketplace for the company's mean shares and marque the shares much accessible to investors." Stock splits bash not alteration thing fundamentally astir a company.
Regencell's surge besides came amid an accrued absorption connected alternate medicines aft Robert F. Kennedy Jr. was sworn successful arsenic Secretary of the U.S. Department of Health and Human Services successful February. Kennedy, a vaccine skeptic, has taken steps to discourage regular immunizations successful the U.S., past week removing each of the members of a panel that advises the Centers for Disease Control and Prevention connected vaccines.
Regencell's banal often makes immense one-day swings. For example, shares jumped astir 30% connected March 21, earlier dropping 30% the pursuing trading day.
Obscure treatments, zero revenue
In spite of the chaotic spike successful the stock, small is known astir the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders.
Regencell's concern centers connected a proprietary Traditional Chinese Medicine look (TCM) developed successful a concern with TCM practitioner Sik-Kee Au utilizing his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell main enforcement officer Yat-Gai Au, the institution said successful a 2022 statement.
Three liquid-based, orally TCM formulae candidates assertion to code mild, mean and terrible conditions and lone incorporate earthy ingredients specified arsenic alleged "detoxication herbs," humor circulation herbs and digestion herbs.
"These TCM formulae signifier the ground of our TCM merchandise candidates, which we mean to make and commercialize for the attraction of ADHD and ASD," Regencell's website reads.
In its latest yearly study filed past October, Regencell said that it had not generated immoderate revenue, nor filed for immoderate regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred full nett losses of $4.36 cardinal and $6.06 million, respectively, according to a 20F filing to the SEC.
"We person not generated gross from immoderate TCM formulae candidates oregon applied for immoderate regulatory approvals, nor person organisation capabilities oregon acquisition oregon immoderate granted patents oregon pending patent applications and whitethorn ne'er beryllium profitable," work the filing.
Regencell has not responded to a CNBC petition for comment.
Regencell's latest diligent lawsuit study, dated Nov. 15, 2023, said 28 patients were fixed the attraction implicit a play of 3 months successful a 2nd efficacy proceedings and showed an betterment successful symptoms of ADHD and ASD, according to the company's webpage.
In an earlier case, Regencell said successful a 2021 news release that it treated a twelve patients with suspected oregon confirmed Covid-19 cases, utilizing a modified mentation of Au's modified proprietary acold and flu TCM formula. What was described arsenic an betterment of Covid conditions led Regencell to signifier a associated task with Honor Epic Enterprises Limited successful Sept. 2021 to behaviour further tests and commercialize the company's Covid attraction successful ASEAN countries, according to the statement.
Online buzz
The banal has attracted small chatter connected societal media implicit the past fewer years. Those comments that person been made suggest some retail trader enthusiasm — and skepticism.
One idiosyncratic connected the Reddit leafage "r/Shortsqueeze" wrote connected Monday that Regencell is "trading similar a meme coin. Bought a small to spot what happens and it dropped 50% close aft lol." Another idiosyncratic said successful a station made 3 months ago, "I scalp RGC mundane for a spot of profit." The banal jumped 1,360% successful May alone.
On LinkedIn successful May, 1 capitalist said helium "can't halt laughing," aft speechmaking the institution description. Another station from a idiosyncratic successful the pharmaceutical industry, according to his profile, past week said Regencell has go the "stock to watch" aft its spike successful May connected "no authoritative quality oregon catalysts." Another LinkedIn idiosyncratic past period commented connected Regencell, saying, "China based, debased measurement and nary authoritative news, bizarro."
On X, 1 idiosyncratic wrote successful a Monday station said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
— CNBC's Scott Schnipper contributed reporting.
English (US) ·